NASDAQ:PRVBProvention Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Provention Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.29 +0.45 (+3.25 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$13.70Now: $14.29▼$14.3950-Day Range$12.19MA: $14.11▼$17.0052-Week Range$4.72Now: $14.29▼$18.50Volume1.35 million shsAverage Volume786,487 shsMarket Capitalization$692.64 millionP/E RatioN/ADividend YieldN/ABeta3.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProvention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Provention Bio has a potential upside of 109.9% from its current price of $14.29.Amount of Analyst CoverageProvention Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesProvention Bio has received 136 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProvention Bio has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentProvention Bio has received 52.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Provention Bio and other stocks. Vote “Outperform” if you believe PRVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRVB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProvention Bio does not currently pay a dividend.Dividend GrowthProvention Bio does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Provention Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,860.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 14.40% of the stock of Provention Bio is held by insiders.Percentage Held by InstitutionsOnly 22.01% of the stock of Provention Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Provention Bio are expected to grow in the coming year, from ($1.21) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Provention Bio is -13.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Provention Bio is -13.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProvention Bio has a P/B Ratio of 8.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRVB Previous Symbol CUSIPN/A CIKN/A Webwww.proventionbio.com Phone908-336-0360Debt Debt-to-Equity RatioN/A Current Ratio11.32 Quick Ratio11.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book8.31Profitability EPS (Most Recent Fiscal Year)($1.06) Net Income$-43,280,000.00 Net MarginsN/A Return on Equity-63.64% Return on Assets-59.28%Miscellaneous Employees13 Outstanding Shares48,470,000Market Cap$692.64 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:PRVB Rates by TradingView Receive PRVB News and Ratings via Email Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter. Provention Bio (NASDAQ:PRVB) Frequently Asked Questions How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)? Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB shares have increased by 58.6% and is now trading at $14.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Provention Bio? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Provention Bio. When is Provention Bio's next earnings date? Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Provention Bio. How were Provention Bio's earnings last quarter? Provention Bio Inc (NASDAQ:PRVB) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. View Provention Bio's earnings history. What price target have analysts set for PRVB? 6 brokers have issued 12-month price targets for Provention Bio's stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Provention Bio's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 109.9% from the stock's current price. View analysts' price targets for Provention Bio. Has Provention Bio been receiving favorable news coverage? Media headlines about PRVB stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Provention Bio earned a news impact score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Provention Bio. Who are some of Provention Bio's key competitors? Some companies that are related to Provention Bio include Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Opko Health (OPK), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), IGM Biosciences (IGMS), Uniqure (QURE), Corcept Therapeutics (CORT), Principia Biopharma (PRNB), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA) and Prestige Consumer Healthcare (PBH). View all competitors. What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS). Who are Provention Bio's key executives? Provention Bio's management team includes the following people: Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)Mr. Cameron Gray Ph.D., MD & Director (Age 46) What is Provention Bio's stock symbol? Provention Bio trades on the NASDAQ under the ticker symbol "PRVB." How do I buy shares of Provention Bio? Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Provention Bio's stock price today? One share of PRVB stock can currently be purchased for approximately $14.29. How big of a company is Provention Bio? Provention Bio has a market capitalization of $692.64 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe. What is Provention Bio's official website? The official website for Provention Bio is www.proventionbio.com. How can I contact Provention Bio? Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
